Biogen Idec and Portola Pharmaceuticals Collaborate on Oral Syk Inhibitors for Autoimmune Diseases
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 11 (Table of Contents)
Published: 7 Nov-2011
DOI: 10.3833/pdr.v2011.i11.1606 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Reflecting its expertise in immunology, Biogen Idec has partnered with Portola Pharmaceuticals’ for the development and commercialisation of Portola’s early-stage oral Syk (spleen tyrosine kinase) inhibitor programme for the treatment of autoimmune and inflammatory diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS